🔎Enjoy our research tool updates? 📃Subscribe to our newsletter to get the latest scientific insights into our portfolio and cancertools.org news✔️

This #PancreaticCancerAwareness month, we highlight the KPC cell line – helping scientists’ study pancreatic tumours more accurately and develop new therapies. Developed by Prof. @jen_morton from @CRUK_SI and made globally accessible by @CancerToolsOrg . Learn more at cancertools.org/advancing-pa… #CancerResearch

We’re excited to exhibit at the 67th ASH Annual Meeting, 6–8 Dec 2025! 📍 Booth #783 — come meet the team and explore our researcher-developed preclinical models, from treatment-resistant myeloma cell lines to CD marker antibodies. As part of @CR_UK - we champion open, collaborative science to accelerate blood cancer research worldwide. Have models in leukaemia, lymphoma, myeloma or other blood cancers? Let’s connect! See you at #ASH2025 — or learn more about us here: cancertools.org/about/ #CancerResearch #BloodCancerResearch #BloodCancer #Myeloma #Leukaemia

We’re exhibiting at #SITC25! 🎉Join @CancerToolsOrg at the Society for Immunotherapy of Cancer Annual Meeting on Nov 7–8 at Booth #924 in National Harbor, MD 🇺🇸 Meet our team, explore researcher-developed tools, and discover how we’re driving cancer drug discovery.🔗 lnkd.in/eWqRcDxb

We’re live at @ELRIG_SCIENCE DrugDiscovery2025! Meet the @CancerToolsOrg team at Booth B30 as we connect with scientists and innovators shaping the future of cancer research. Discover how our cell lines, antibodies & PDX models are accelerating global cancer discoveries. #ELRIGDD25 #CancerResearch #OpenScience #CancerTools #OncologyResearch

🕕 Less than a week until #ELRIGDD25! Join CancerTools.org at Booth B30 to explore 1,500 human & animal cancer cell lines powering global drug discovery, many developed with our partner @CR_UK 📅 21–22 Oct 2025 | 📍 Liverpool, UK 🌐 cancertools.org #DrugDiscovery #CancerResearch

📢 Excited to announce we’ll be at #ELRIGDD25! 📅 21–22 Oct 2025 | 📍 Booth B30, Liverpool, UK Visit @CancerToolsOrg – home to 1,500 trusted cancer research cell lines (including BICR, KPC, PEO & more), many developed through @CR_UK funded research. Empowering scientists to accelerate cancer discovery. 💙 Explore our collection 👉 lnkd.in/emisQFSj

🔬 Ready to capture the complexity of #BladderCancer in your lab? Its molecular diversity and dynamic tumour microenvironment make translational research challenging. 🧬 At CancerTools.org (@CancerToolsOrg), a non-profit #biorepository offers curated bladder cancer cell lines to help you advance therapeutic discovery: ✅ MB49 & MB49-Luciferase ✅ UM-UC panel ✅ RT112/84 ✅ NCI-HPN lines 👉 Explore now: lnkd.in/eGHZBeqT

🚀 Thrilled to share CancerTools.org has been featured in @SelectScience ! Our very own colleagues, James Ritchie and Natalie Harker reveal how we’re accelerating cancer research to be faster, more accessible & collaborative. 🙏 Thanks to @SelectScience & all advancing this vital field. 🔗 lnkd.in/eKr9qxQf

💛 September is #ChildhoodCancerAwarenessMonth. At @CancerToolsOrg (part of @CR_UK), we share research tools worldwide to accelerate discoveries & advance treatments. Together, we can turn research into impact. 👉 lnkd.in/eesR8BfC

Every tool we equip scientists helps researchers move closer to breakthroughs in ovarian & other gynae cancers. From lab bench to real-world impact, we stand with @CR_UK & the global research community this #GynaecologicalCancerAwareness Month. Explore our resources: cancertools.org/research-too…

Why are more researchers choosing Plasmax™ cell culture medium? Dr. Sunada Khadka, a former researcher at @MDAndersonNews discovered that using traditional media like DMEM can significantly inflate in vitro drug efficacy. In her research on ENO1-deleted glioma cells, Sunada initially observed strong in vitro drug responses in DMEM, showing notable efficacy and synergy between HEX and CB-839 inhibitors. However, these effects were significantly reduced in vivo, raising concerns with traditional culture media. The turning point? Using Plasmax™ 🔍 With Plasmax™, Sunada uncovered: ➤ Reduced CB-839 toxicity in glioma cells under physiological conditions ➤ Loss of in vitro CB-839 & HEX synergy (previously observed in DMEM) ➤ Evidence that DMEM inflated in vitro drug performance This case study underscores the importance of media choice in preclinical cancer research. Plasmax™ better replicates the in vivo tumour metabolic environment than traditional media, like DMEM. This supports the generation of more reliable and translatable drug response data. Read the full case study here ➡️lnkd.in/eQRcsX2m

📍 We’re live at #ADLM2025! Come visit us at Booth #1762 and meet our dedicated licensing team. Whether you're exploring collaboration opportunities or looking for the right license partner to drive your innovation, we're here to help guide you through the process. 🏢 McCormick Place Convention Center 🌐 Chicago, IL. USA 📅 29 - 31 July 2025 We can leverage research tools and technologies developed at @CR_UK and other world-leading cancer institutes, helping you accelerate progress in drug discovery, disease modelling and in-vitro diagnostics. Let’s connect, discuss your commercial needs, and explore how we can support your journey. Can't attend the conference? Visit our website to learn more: lnkd.in/eMF4xnzi #ADLM2025 #LifeSciences #Licensing #CancerResearch #BiotechInnovation #Partnerships #Commercialisation #OncologyResearch #ScientificAdvancements

📣 We’re excited to share that CancerTools.org is featured in @SelectScience 💯 As a non-profit, global cancer-focused research tools biorepository, we’re proud to be spotlighted for our mission to accelerate cancer discoveries by providing scientists with the tools they need to drive innovation 📄 Explore our dedicated page on @SelectScience to learn more about how we’re supporting cancer researchers worldwide, from academic labs to biotech and pharma: 👉selectscience.net/company/ca… 🆕 Also don’t miss out on our latest featured resource: “Advancing cancer cell biology with a physiologically relevant cell culture medium” Explore how innovations in cell culture media can improve the physiological relevance of in vitro cancer models. 👉 selectscience.net/resources?… selectscience.net/company/ca…

🌏 World Head and Neck Cancer Day | 27 July  🌏 🔍 Observed annually on July 27th, World Head and Neck Cancer Day raises global awareness of head and neck cancers, highlighting their risk factors and emphasising the critical role of early detection in improving outcomes. 🏢 Through our non-profit biorepository, we provide scientists with access to tools developed by leading experts. From cell lines to antibodies, these resources are essential for, drug discovery, and translational research in head and neck cancer. 💫 By making these tools globally accessible, we aim to accelerate scientific discovery and drive innovation in cancer research. 🔗 Discover more at: lnkd.in/ePz2EaR8

We’re thrilled to be joining the scientific community at #ADLM2025 from 27–31 July 2025, hosted @myADLM. Visit us at Booth 1762 to explore our comprehensive collection of cancer research tools, expertly curated to support breakthroughs across academia, biotech, and pharma. Whether you're scaling R&D, building new assays, or accelerating preclinical discovery, we work closely with our partners to offer a range of licensing options tailored to your specific needs and the types of tools you wish to access. ✅ Dedicated licensing team of contract and compliance experts. ✅ Access to novel, peer-reviewed tools with commercial potential ✅ Speed up proof of concept and validation ✅ 100% non-profit. 100% focused on cancer. Let’s connect at #ADLM2025 - Booth 1762 or visit our website to learn more: lnkd.in/eMF4xnzi #cancerresearch #Oncology

🚨 NEW PRODUCT ALERT 🚨 We're excited to share that the CRUK Lung Cancer Centre of Excellence at UCL has deposited 44 groundbreaking #TRACERx non-small cell lung cancer (NSCLC) PDX models with @CancerToolsOrg - cancertools.org/pdx-models/?… Lung cancer is the leading cause of cancer-related deaths, with intratumor heterogeneity posing a significant challenge to treatment. Patient-Derived Xenograft (PDX) models offer several key advantages over traditional models, including: ✅ Higher translatability due to better recapitulation of source patient intratumor heterogeneity and drug responses ✅ Increased accuracy for disease modelling and preclinical in vivo studies Our new NSCLC PDX models, developed from multiple regions of primary tumours from Lung #TRACERx study patients, were created by Dr Robert Hynds and David Pearce at the @uclcancer Read the full launch announcement to learn more about these new #TRACERx NSCLC PDX models. Access here: cancertools.org/nsclc-pdx-mo…